KRYS Q3 FY26 earnings call: key takeaways

• EPS of $2.05 beat the $1.84 consensus (5:00)
• The results reflect a profitable business with strong commercial growth and a robust pipeline. (1:49)

Results vs expectations

EPS basis: GAAP diluted EPS, SEC 10-Q

The stock moved -11.0% over the report window (S&P 500 ETF -0.5%). Earnings history

What changed since last quarter

• The company raised its full year non-GAAP R&D and SG&A guidance to $155 to $165 million from $175 to $195 million. (20:59)
• The company authorized a $400 million share repurchase program, reflecting confidence in long-term prospects. (1:49)
• The company expects to launch Vyjuvex in Italy in early 2027 and in Spain by year-end. (6:59)

What analysts pressed on

• Whether the slower enrollment in the NK program will impact the timeline for data readouts. (29:30)
• How the company plans to address the challenges in enrolling patients for the NK program. (27:30)
• Concerns about the impact of pricing negotiations in France on future revenue. (42:37)

In their words

• We have a rich pipeline with several important readouts in the upcoming months. Krish (22:42)
• We are making great progress on our in-health KB707 program... (16:00)
• The initial Gorlin findings are very encouraging, and we look forward to the upcoming Haley-Haley results... Krish (22:42)